New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:07 EDTAMPEAmpio' subisidary establishes study collaboratoins with two research centers
Ampio announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center and the University of Thessaly. These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:49 EDTAMPEAmpio announces STRIDE study AP008 did not reach its primary endpoint
Ampio Pharmaceuticals announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion. This pain reduction with Ampion was consistent across all sites and with our previously reported studies Ampion is safe and well tolerated. Ampio Pharmaceuticals launched the Phase III program for AmpionTM to treat pain due to osteoarthritis, OA, of the knee. Each patient received three 4ml intra-articular injections of Ampion, or the saline placebo, one at baseline, the second at two weeks and the third at four weeks. In OA, saline is known to be a partial therapeutic and not a true placebo, but has been the control used in all published OA drug trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use